FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.
Stakeholders hoping for hints about President Biden’s plans for the US Food and Drug Administration in his fiscal year 2022 budget outline were left wanting, but the lack of any real information is not surprising or necessarily conclusion-generating.
Biden’s FY 2022 so-called “skinny” budget request, a 58-page summary of top-line figures and themes in his spending wish...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
